ABACUS MEDICINE A/S: Financial statements 2013
CVR: 28111576
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
ABACUS MEDICINE A/S (CVR 28111576) has filed annual accounts for 2013. In 2013, the company reported revenue of DKK 489,457,000 and a net result of DKK 5,653,000. The profit margin was 1.2%. Equity in the 2013 report amounted to DKK 6,122,000. The solvency ratio was 8.3%. The company had 40 employees in the financial year.
- Revenue
- DKK 489,457,000
- Gross Profit
- DKK 35,713,000
- Profit/Loss
- DKK 5,653,000
- Equity
- DKK 6,122,000
- Total Assets
- DKK 74,113,000
- Employees
- 40
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of September 12, 2013, EY Godkendt Revisionspartnerselskab has been appointed auditor of ABACUS MEDICINE A/S.
As of August 29, 2013, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of ABACUS MEDICINE A/S.
As of August 28, 2013, Troels Peter Troelsen has joined the board of directors of ABACUS MEDICINE A/S.
As of August 28, 2013, Lars Christian Bruhn has left the board of directors of ABACUS MEDICINE A/S.
ABACUS MEDICINE A/S has published its annual report for 2012.
As of May 31, 2013, Lars Aaen has joined the board of directors of ABACUS MEDICINE A/S.
About ABACUS MEDICINE A/S
ABACUS MEDICINE A/S is a Danish company of the type Aktieselskab based in København V, founded in 2004. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ABACUS MEDICINE ApS. The management consists of Flemming Wagner. The board consists of Jens Albert Harsaae (chair), Alette Margaretha Verbeek, Anders Kunze Bønding and Flemming Wagner. The company is owned by Wagner Family Holding ApS and CHR. AUGUSTINUS FABRIKKER AKTIESELSKAB. The company has 388 employees (2026). In 2025, the company reported revenue of EUR 1,817,637,000 and a net result of EUR 7,779,000 compared with EUR 17,621,000 the year before. Equity in the 2025 report amounted to EUR 98,523,000.